U.S. Luxury Stock News

NasdaqCM:EXAS
NasdaqCM:EXASBiotechs

Did Oncotype DX’s 2 Millionth Patient Milestone Just Shift Exact Sciences’ (EXAS) Investment Narrative?

In early February 2026, Exact Sciences reported that its Oncotype DX Breast Recurrence Score test has now guided treatment decisions for more than two million early-stage HR+, HER2- breast cancer patients worldwide, supported by over two decades of clinical evidence and broad global adoption. The company highlighted that Oncotype DX remains the only genomic assay proven to be both prognostic and predictive for chemotherapy benefit, with published models suggesting meaningful lifetime cost...
NasdaqGS:RBBN
NasdaqGS:RBBNCommunications

A Look At Ribbon Communications (RBBN) Valuation After 2025 Results And 2026 Revenue Guidance

Why Ribbon Communications is back on investor radar Ribbon Communications (RBBN) has drawn attention after reporting fourth quarter and full year 2025 results alongside fresh 2026 revenue guidance, giving investors updated numbers on profitability and the coming year. The company reported fourth quarter 2025 revenue of US$227.32 million compared with US$251.36 million a year earlier, while net income moved to US$89.07 million from US$6.36 million. Full year revenue was US$844.56 million...
NYSE:HP
NYSE:HPEnergy Services

Helmerich & Payne Debt Cut Highlights Cash Generation And Dividend Resilience

Helmerich & Payne (NYSE:HP) recently reduced its term loan by US$260 million ahead of schedule. The company reported strong free cash flow while covering rig reactivation costs in international markets. Dividends were maintained even as the rig market has been soft. For you as an investor, this mix of debt reduction and steady cash generation is a notable development. Helmerich & Payne is a contract driller focused on providing rigs and related services to energy producers, a segment that...
NasdaqGS:TECH
NasdaqGS:TECHLife Sciences

Is It Time To Reassess Bio-Techne (TECH) After Years Of Share Price Weakness?

If you are wondering whether Bio-Techne is attractively priced or just fairly valued right now, you are in the right place to put some structure around that question. Bio-Techne's share price last closed at US$66.78, with returns of 2.3% over 7 days, 1.6% over 30 days, 12.0% year to date, but a 3.9% decline over 1 year, a 12.2% decline over 3 years and a 31.7% decline over 5 years. Recent attention on the stock has been shaped by ongoing interest in life sciences tools companies and how...
NYSE:PSTG
NYSE:PSTGTech

Hesai Group And 2 Other Stocks That May Be Priced Below Intrinsic Value

As the United States stock market kicks off February with a strong surge, evidenced by the Dow Jones Industrial Average's 515-point gain and the S&P 500 nearing record highs, investors are keenly observing which stocks could be undervalued amidst this positive momentum. In such an environment, identifying stocks that may be priced below their intrinsic value can present opportunities for investors looking to capitalize on potential growth while navigating current economic developments.
NasdaqCM:CORT
NasdaqCM:CORTPharmaceuticals

Three High Growth Companies With Significant Insider Ownership

As February begins, major U.S. stock indexes have started the month on a high note, with the Dow Jones Industrial Average adding 515 points and the S&P 500 nearing record levels. In this buoyant market environment, investors often look for growth companies with significant insider ownership as these stocks can indicate strong confidence from those closest to the business.
NasdaqGS:NMRA
NasdaqGS:NMRAPharmaceuticals

3 Promising Penny Stocks With Market Caps Up To $400M

The U.S. stock market kicked off February with a strong performance, as major indexes like the Dow Jones and S&P 500 posted significant gains. Amidst this backdrop of optimism, investors are exploring various opportunities across different market segments. While penny stocks might seem like a throwback to earlier trading days, they continue to offer intriguing possibilities for those interested in smaller or emerging companies with potential growth prospects.
NasdaqGS:CTBI
NasdaqGS:CTBIBanks

Discovering US Market's Undiscovered Gems in February 2026

As February 2026 unfolds, the U.S. stock market has kicked off the month with a robust upswing, as evidenced by significant gains in major indices like the Dow Jones Industrial Average and S&P 500. Amid this bullish sentiment, small-cap stocks are garnering attention due to their potential for growth and resilience in a fluctuating economic landscape. In this dynamic environment, identifying promising stocks requires an understanding of how these companies can capitalize on current market...
NYSE:YRD
NYSE:YRDConsumer Finance

Top Dividend Stocks To Consider In February 2026

As February 2026 begins, U.S. stock markets have surged with the Dow Jones Industrial Average climbing by 515 points and the S&P 500 nearing record highs, reflecting a positive start to the month despite ongoing economic uncertainties such as trade negotiations and government shutdowns. In this environment of market optimism, dividend stocks can offer investors a compelling combination of potential income and stability, making them an attractive consideration for those looking to navigate...
NYSE:VTR
NYSE:VTRHealth Care REITs

Why Ventas (VTR) Is Up 6.6% After Dividend Hike And 2026 Earnings Guidance And What's Next

Ventas, Inc. recently reported its fourth-quarter and full-year 2025 results, showing higher revenue of US$1.57 billion and net income of US$70.20 million for the quarter, alongside an 8% increase in its quarterly dividend to US$0.52 per share payable on April 16, 2026. Management also issued 2026 guidance for attributable net income per share of US$0.52–US$0.62 and funds from operations of US$3.78–US$3.88 per share, underscoring how senior housing investments and improved operating metrics...